← Back to Screener
AgomAb Therapeutics NV American Depositary Shares (AGMB)
Price$10.79
Favorite Metrics
Price vs S&P 500 (4W)-16.55%
Market Capitalization$329,816.469
All Metrics
Price vs S&P 500 (YTD)-25.49%
10-Day Avg Trading Volume0.22M
EPS (Annual)$-1.12
ROI (Annual)-24.40%
ROA (Last FY)-22.42%
Cash Flow / Share (Annual)$-0.00
P/B Ratio0.00x
Net Income / Employee (Annual)$-1
EPS Incl Extra (Annual)$-1.12
Current Ratio (Annual)19.05x
Quick Ratio (Quarterly)13.99x
3-Month Avg Trading Volume0.23M
52-Week High$17.45
EPS Excl Extra (Annual)$-1.12
Quick Ratio (Annual)19.05x
Total Debt / Equity (Annual)0.01x
Current Ratio (Quarterly)13.99x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.00
ROE (Last FY)-24.60%
EPS Basic Excl Extra (Annual)$-1.12
Total Debt / Equity (Quarterly)0.01x
Revenue / Share (Annual)$0.00
Year-to-Date Return-22.66%
5-Day Price Return8.73%
EPS Normalized (Annual)$-1.12
Month-to-Date Return8.01%
EBITD / Share (Annual)$-1.15
LT Debt / Equity (Annual)0.00x
Beta1.58x
52-Week Low$9.00
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AGMBAgomAb Therapeutics NV American Depositary Shares | — | — | — | — | $10.79 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing small molecule and antibody therapies for chronic fibrotic diseases and related immunological disorders with significant unmet medical needs. The company's pipeline targets established inflammatory pathways using validated modalities, with lead candidates Ontunisertib (AGMB-129) and AGMB-447. AgomAb's approach aims to overcome limitations of existing treatment options for fibrotic indications.